<DOC>
	<DOCNO>NCT01268566</DOCNO>
	<brief_summary>The primary objective Phase II study evaluate progression-free survival 6 month adult subject first recurrence Glioblastoma Multiforme treat MEDI-575 .</brief_summary>
	<brief_title>A Study MEDI-575 Subjects With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>This Phase 2 , multicenter , open-label , single-arm study evaluate antitumor activity , safety , pharmacology MEDI-575 adult subject first recurrence GBM . Approximately 55 subject enrol determine preliminary efficacy profile MEDI-575 treatment subject first recurrence GBM . Subjects receive MEDI-575 60-minute IV infusion Day 1 every 21 day disease progression , initiation alternative anticancer therapy , unacceptable toxicity , reason subject withdrawal . The primary assessment antitumor activity PFS-6 ; tumor response progression determine use Updated Response Assessment Criteria High Grade Gliomas- Neuro-Oncology Working Group v.1 . Approximately 15 investigational site United States participate study . All subject follow every 3 month duration trial ( defined 9 month date last subject enter trial sponsor stop study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Written inform consent HIPAA authorization ( applies cover entity USA ) obtain subject/legal representative prior performing protocolrelated procedure , include screen evaluation Age ≥18 year old time screen Histologically confirm diagnosis World Health Organization Grade IV malignant glioma ( glioblastoma gliosarcoma ) Previous first line treatment radiotherapy temozolomide ( treatment prior radiation temozolomide permit , [ ie , Gliadel ] ) Documented first recurrence GBM diagnostic biopsy contrastenhanced magnetic resonance imaging ( MRI ) per Updated Response Assessment Criteria High Grade Gliomas NeuroOncology Working Group ( Wen et al , 2010 ) Life expectancy ≥ 12 week Adequate hematologic organ function Negative serum pregnancy test ( woman ) Two method birth control female participant childbearing potential male participant female partner childbearing potential Treatment chemotherapy , radiotherapy , immunotherapy , biologic , hormonal therapy investigational agent 30 day prior study entry Concurrent enrollment another clinical study involve investigational agent Employees clinical study site individual involve conduct study , immediate family member individual Previous mAb treatment specifically direct PDGF PDGF receptor Previous bevacizumab VEGF antiangiogenic treatment More 1 recurrence GBM Any surgery ( include minor diagnostic procedure ) within 2 week prior baseline disease assessment ; fully recover side effect previous procedure History serious allergy reaction component MEDI575 formulation New York Heart Association ≥ Grade 2 congestive heart failure within 6 month prior study entry Uncontrolled significant cardiovascular disease History invasive malignancy within 5 year prior study entry except cervical carcinoma situ ( CIS ) , nonmelanomatous carcinoma skin ductal carcinoma situ ( DCIS ) breast surgically cure History active human immunodeficiency virus active hepatitis B C viral infection exclude eliminate risk increase AEs due immune compromise . Systemic immunosuppressive therapy . Subjects take corticosteroid must stable dose 7 day prior initiation treatment MEDI575 16 ) Presence extracranial metastatic leptomeningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Glioblastoma</keyword>
</DOC>